News - Anti-virals


Current filters:


Popular Filters

151 to 175 of 420 results

Gilead’s HIV drug booster Tybost gets EU marketing authorization

Gilead’s HIV drug booster Tybost gets EU marketing authorization


US biotech major Gilead Sciences has received marketing authorization from the European Commission for…

Anti-viralsBiotechnologyEuropeGilead SciencesNorth AmericaRegulationTybost

MSF warns of US/Indian tension over generic policy discussion

MSF warns of US/Indian tension over generic policy discussion


Humanitarian group Médecins Sans Frontières has warned that India is facing political pressure from…

Anti-viralsAsia-PacificBayerGenericsGleevecHealthcareNexavarNorth AmericaNovartisPolitics

Stribild in HIV shows lesser benefit for treatment-naive patients, says IQWiG

Stribild in HIV shows lesser benefit for treatment-naive patients, says IQWiG


In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

Anti-viralsBiotechnologyEuropeGilead SciencesPricingRegulationStribild

ViiV Healthcare presents positive Tivicay results from HIV study


Positive data has been reported from the Phase IIIb/IV FLAMINGO study of Tivicay (dolutegravir) versus…

Anti-viralsNorth AmericaPharmaceuticalResearchTivicayViiV Healthcare

Valneva enters deals with Delta-Vir


Biotech firm Valneva (Euronext: VLA), the company recently created through the merger of France's Vivalis…


AHF sues GSK for failing to provide discounts on HIV/AIDS drugs


The USA-based AIDS Healthcare Foundation (AHF) said yesterday (September 10) that it has filed a law…

Anti-viralsGlaxoSmithKlineLegalNorth AmericaPharmaceuticalPricing

Roche in up to $422.5 million deal with Inovio Pharma


Swiss drug major Roche (ROG: SIX) has signed an exclusive, worldwide license agreement with US drug developer…

Anti-viralsINO-1800INO-5150Inovio PharmaceuticalsLicensingOncologyPharmaceuticalRoche

Boehringer Ingelheim links with Presidio on interferon-free hepatitis C treatment regimens


The US subsidiary of German family-owned drug major Boehringer Ingelheim says it has completed patient…

Anti-viralsBoehringer IngelheimdeleobuvirfaldaprevirPharmaceuticalPPI-668Presidio PharmaceuticalsResearch

Medivir and Daewoong drop hep C drug candidate


Swedish infectious disease drug developer Medivir (STO:MVIR-B) said on Friday (September 6) that it has…


In wake of Tivicay approval, MSF asks, "when will people in developing countries have access?"


As the US Food and Drug Administration approved the new HIV drug Tivicay (dolutegravir) late Monday (The…

Anti-viralsdolutegravirGlobalHealthcarePharmaceuticalPricingTivicayViiV Healthcare

FDA approves new ViiV Healthcare HIV drug


The US Food and Drug Administration yesterday (August 12) approved Tivicay (dolutegravir), a new drug…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

AHF claims victory over FDA in HIV prevention drug case


The USA-based AIDS Healthcare Foundation (AHF) says it won a key legal victory in a push for drug safety…

Anti-viralsBiotechnologyGilead SciencesLegalNorth AmericaPharmaceuticalRegulationTruvada

US FDA approves shipment of quadrivalent flu vaccine to health care providers


The US subsidiary of UK pharma giant GlaxoSmithKline (LSE: GSK) says it has received Food and Drug Administration…

Anti-viralsFluarixGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationVaccines

Roche strikes deal with Medicines Patent Pool on medicines access


Swiss drug major Roche (ROG: SIX) has entered into an agreement with the Medicines Patent Pool, a Geneva,…

Anti-viralsMarkets & MarketingPharmaceuticalPricingRocheValcyte

Campaign group's concern at blocks on India's generic exports


An HIV and AIDS campaigner has written an open letter to the US government in protest at what it calls…

Anti-viralsBayerGenericsHealthcareNatco PharmaRest of the WorldSorafenib

Vertex slumps as FDA delays hepatitis C trial


US drug maker Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares drop 11% to $78 a share, in after-hours…

Anti-viralsBiotechnologyNorth AmericaPharmaceuticalRegulationResearchVertexVX-135

New Zealand consults on Victrelis listing and some Pegasys amendments


New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list boceprevir…

Anti-viralsAsia-PacificBiotechnologyMerck & CoPegasysPharmaceuticalRegulationRocheVictrelis

UK's NICE recommends hepatitis C treatment for children


In draft guidance published this week, the UK's drugs watchdog the National Institute for Health and…

Anti-viralsBiotechnologyEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferonPeg

Annual approvals of new drugs for neglected diseases nearly doubled since early 2000s and 2009-12; Tufts


The annual number of new drug approvals worldwide to treat neglected diseases has nearly doubled in recent…

Anti-viralsPharmaceuticalRegulationResearchTropical diseases

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs


Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…


Immune Design and Medicago link up to develop flu vaccines


Privately-held US biotech firm Immune Design and Medicago (TSX: MDG), a Canadian biopharmaceutical company…

Anti-viralsBiotechnologyImmune DesignLicensingMedicagoVaccines

Idenix Pharma slumps as FDA calls for more data on IDX20963


USA-based biotech firm Idenix Pharmaceuticals (Nasdaq: IDIX) saw its share price plunge as much as 31.8%…

Anti-viralsBiotechnologyIdenix PharmaceuticalsIDX20963North AmericaRegulation

151 to 175 of 420 results

Back to top